One of the many aims of President Joe Biden’s signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 and over. But the policy could have some side-effects for patients far beyond the US.
Hosts: Tom Lee-Devlin and Mike Bird. Contributors: Shailesh Chitnis, The Economist’s global business correspondent; Tricia Neuman, from the Kaiser Family Foundation, a health-care think-tank; and David Fredrickson of AstraZeneca.
Sign up for Economist Podcasts+ now and get 50% off your subscription with our limited time offer: www.economist.com/podcastsplus-moneytalks
You will not be charged until Economist Podcasts+ launches. If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription. For more information about Economist Podcasts+, including how to get access, please visit our FAQs page.
","author_name":"The Economist"}